MR-proANP improves prediction of mortality and cardiovascular events in patients with STEMI

European Journal of Preventive Cardiology

Volumn 22, Issue 6, 2015, Pages 693-700

  Lindberg, Søren ^a   Jensen, Jan Skov ^a,b   Pedersen, Sune H ^a   Galatius, Søren ^a   Goetze, Jens P ^c   Mogelvang, Rasmus ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c University of Copenhagen   (Denmark)

Author keywords

myocardial infarction; outcome; proANP; STEMI

Indexed keywords

ACETYLSALICYLIC ACID; ATRIAL NATRIURETIC FACTOR; C REACTIVE PROTEIN; CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MIDREGIONAL PRO ATRIAL NATRIURETIC PEPTIDE; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; MIDREGIONAL PRO-ATRIAL NATRIURETIC PEPTIDE, HUMAN; TROPONIN I;

ADULT; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; COMPARATIVE STUDY; ECHOCARDIOGRAPH; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT BUNDLE BRANCH BLOCK; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; ST SEGMENT ELEVATION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; ADVERSE EFFECTS; AGED; AREA UNDER THE CURVE; BLOOD; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; HOSPITAL READMISSION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME; UPREGULATION;

AGED; AREA UNDER CURVE; ATRIAL NATRIURETIC FACTOR; BIOMARKERS; C-REACTIVE PROTEIN; CAUSE OF DEATH; FEMALE; HEART FAILURE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PATIENT READMISSION; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; STROKE; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; TROPONIN I; UP-REGULATION; VENTRICULAR FUNCTION, LEFT;

EID: 84929082079     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/2047487314538856     Document Type: Article

References (24)

1. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. New Engl J Med. 1998; 339: 321-328
2. de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. New Engl J Med. 2001; 345: 1014-1021
3. Bassan R, Potsch A, Maisel A, et al. B-type natriuretic peptide: a novel early blood marker of acute myocardial infarction in patients with chest pain and no ST-segment elevation. Eur Heart J. 2005; 26: 234-240
4. Lainchbury JG, Troughton RW, Strangman KM, et al. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol. 2009; 55: 53-60
5. Maisel A, Mueller C, Adams K Jr, et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail. 2008; 10: 824-839
6. Ala-Kopsala M, Magga J, Peuhkurinen K, et al. Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A-and B-type natriuretic peptides. Clin Chem. 2004; 50: 1576-1588
7. Morgenthaler NG, Struck J, Thomas B, et al. Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem. 2004; 50: 234-236
8. von Haehling S, Jankowska EA, Morgenthaler NG, et al. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure. J Am Coll Cardiol. 2007; 50: 1973-1980
9. Maisel A, Mueller C, Nowak R, et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol. 2010; 55: 2062-2076
10. Sabatine MS, Morrow DA, de Lemos JA, et al. Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease. Circulation. 2012; 125: 233-240
11. Meune C, Twerenbold R, Drexler B, et al. Midregional pro-A-type natriuretic peptide for diagnosis and prognosis in patients with suspected acute myocardial infarction. Am J Cardiol. 2012; 109: 1117-1123
12. Bjerre M, Pedersen SH, Mogelvang R, et al. High osteopontin levels predict long-term outcome after STEMI and primary percutaneous coronary intervention. Eur J Prev Cardiol. 2013; 20: 922-929
13. Madsen M, Davidsen M, Rasmussen S, et al. The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry. J Clin Epidemiol. 2003; 56: 124-130
14. Hunter I, Alehagen U, Dahlstrom U, et al. N-terminal pro-atrial natriuretic peptide measurement in plasma suggests covalent modification. Clin Chem. 2011; 57: 1327-1330
15. Vervoort G, Klein Gunnewiek JM, Willems HL, et al. Effect of creatinine assay standardization on the performance of Cockcroft-Gault and MDRD formula in predicting GFR. Nephrol Dial Transplant. 2006; 21: 2998-2999
16. Vesely DL. Atrial natriuretic peptide prohormone gene expression: hormones and diseases that upregulate its expression. IUBMB Life. 2002; 53: 153-159
17. Omland T, Aakvaag A, Bonarjee VV, et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation. 1996; 93: 1963-1969
18. von Haehling S, Papassotiriou J, Hartmann O, et al. Mid-regional pro-atrial natriuretic peptide as a prognostic marker for all-cause mortality in patients with symptomatic coronary artery disease. Clin Sci (Lond). 2012; 123: 601-610
19. Tzikas S, Keller T, Ojeda FM, et al. MR-proANP and MR-proADM for risk stratification of patients with acute chest pain. Heart. 2013; 99: 388-395
20. Khan SQ, Dhillon O, Kelly D, et al. Plasma N-terminal B-type natriuretic peptide as an indicator of long-term survival after acute myocardial infarction: comparison with plasma midregional pro-atrial natriuretic peptide: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. J Am Coll Cardiol. 2008; 51: 1857-1864
21. Sabatine MS, Morrow DA, de Lemos JA, et al. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J Am Coll Cardiol. 2004; 44: 1988-1995
22. Jarai R, Iordanova N, Raffetseder A, et al. Risk assessment in patients with unstable angina/non-ST-elevation myocardial infarction and normal N-terminal pro-brain natriuretic peptide levels by N-terminal pro-atrial natriuretic peptide. Eur Heart J. 2005; 26: 250-256
23. Moertl D, Berger R, Struck J, et al. Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death. J Am Coll Cardiol. 2009; 53: 1783-1790
24. Elmas E, Brueckmann M, Lang S, et al. Midregional pro-atrial natriuretic peptide is a useful indicator for the detection of impaired left ventricular function in patients with coronary artery disease. Int J Cardiol. 2008; 128: 244-249